Loading organizations...
§ Private Profile · Paris, Ile-de-France, France
Medtech company developing FDA-cleared AI software for prenatal ultrasound exams, focused on real-time fetal heart defect detection.
Based in Paris, France, BrightHeart develops artificial intelligence software as a medical device designed to assist clinicians in detecting congenital heart defects during routine prenatal ultrasound exams. The company's FDA-cleared technology provides real-time analysis of the fetal heart to improve exam completeness and accuracy for obstetricians, gynecologists, and sonographers. Operating with a team of 10 employees, the medtech firm secured an €11 million Series A funding round in January 2026 to scale its commercial deployment across healthcare providers in the United States and Europe. This financing was co-led by Odyssée Venture and GO Capital, with continued backing from its incubator, Sofinnova Partners. The enterprise also collaborates with pediatric cardiologists from prominent institutions such as Necker Hospital and Stanford University to validate its clinical applications. BrightHeart was officially founded in 2022 by Marilyne Lévy and Bertrand Stos.
BrightHeart has raised $15.0M across 2 funding rounds.
BrightHeart has raised $15.0M in total across 2 funding rounds.
BrightHeart has raised $15.0M across 2 funding rounds. Most recently, it raised $12.8M Series A in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 8, 2026 | $12.8M Series A | Leila Nicolas Guerlain, Julien Andrieux | John Gridley, Laurent Salomon, Sacha Loiseau, Orin Herskowitz, IDAHO HealthTech Club, Lift Value, Cécile Dupont Redon | Announced |
| May 31, 2023 | $2.1M Seed | Sofinnova Partners | — | Announced |
BrightHeart has raised $15.0M in total across 2 funding rounds.
BrightHeart's investors include Leila Nicolas Guerlain, Julien Andrieux, John Gridley, Laurent SALOMON, Sacha Loiseau, Orin Herskowitz, IDAHO HealthTech Club, Lift Value, Cécile Dupont Redon, Sofinnova Partners.